Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Cash Flow-to-Debt Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Cash Flow-to-Debt Ratio of 0.09x as of September 2025, meaning its operating cash flow of CN¥61.35 Million could theoretically repay 0% of its total liabilities (CN¥692.94 Million) in one year. Check 688513 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chengdu Easton Biopharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Chengdu Easton Biopharmaceuticals Co Ltd across 12 annual periods. Also explore 688513 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Chengdu Easton Biopharmaceuticals Co Ltd. For market capitalisation and broader financial context, see 688513 market cap.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.37x | CN¥263.24 Million | CN¥702.21 Million | ▲ +1.2% |
| 2023 | 0.37x | CN¥275.25 Million | CN¥743.33 Million | ▲ +39.7% |
| 2022 | 0.27x | CN¥151.94 Million | CN¥573.08 Million | ▼ -13.1% |
| 2021 | 0.31x | CN¥147.60 Million | CN¥483.60 Million | ▼ -15.1% |
| 2020 | 0.36x | CN¥156.52 Million | CN¥435.61 Million | ▼ -26.6% |
| 2019 | 0.49x | CN¥141.83 Million | CN¥289.64 Million | ▼ -39.1% |
| 2018 | 0.80x | CN¥166.79 Million | CN¥207.50 Million | ▲ +37.6% |
| 2017 | 0.58x | CN¥85.70 Million | CN¥146.70 Million | ▼ -28.2% |
| 2016 | 0.81x | CN¥106.06 Million | CN¥130.43 Million | ▼ -30.2% |
| 2015 | 1.16x | CN¥50.57 Million | CN¥43.42 Million | ▲ +99.1% |
| 2014 | 0.59x | CN¥46.71 Million | CN¥79.85 Million | ▲ +79.4% |
| 2013 | 0.33x | CN¥28.12 Million | CN¥86.24 Million | — |